Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Receivables (2024 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Receivables for 2 consecutive years, with $13000.0 as the latest value for Q4 2025.

  • Quarterly Receivables fell 98.35% to $13000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13000.0 through Dec 2025, down 98.35% year-over-year, with the annual reading at $13000.0 for FY2025, 98.35% down from the prior year.
  • Receivables hit $13000.0 in Q4 2025 for Connect Biopharma Holdings, down from $17000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $789000.0 in Q4 2024 to a low of $8000.0 in Q1 2025.